KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Income: 2021-2025

Historic Non Operating Income for Xenon Pharmaceuticals (XENE) over the last 4 years, with Sep 2025 value amounting to $6.1 million.

  • Xenon Pharmaceuticals' Non Operating Income fell 42.11% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year decrease of 25.45%. This contributed to the annual value of $40.9 million for FY2024, which is 30.32% up from last year.
  • Xenon Pharmaceuticals' Non Operating Income amounted to $6.1 million in Q3 2025, which was down 31.25% from $8.9 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Non Operating Income's 5-year high stood at $11.5 million during Q1 2024, with a 5-year trough of -$2.7 million in Q1 2022.
  • For the 3-year period, Xenon Pharmaceuticals' Non Operating Income averaged around $8.7 million, with its median value being $8.1 million (2025).
  • In the last 5 years, Xenon Pharmaceuticals' Non Operating Income spiked by 3,023.55% in 2022 and then crashed by 42.11% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Non Operating Income (Quarterly) stood at -$242,000 in 2021, then skyrocketed by 3,023.55% to $7.1 million in 2022, then grew by 23.63% to $8.7 million in 2023, then declined by 9.18% to $7.9 million in 2024, then slumped by 42.11% to $6.1 million in 2025.
  • Its Non Operating Income was $6.1 million in Q3 2025, compared to $8.9 million in Q2 2025 and $8.1 million in Q1 2025.